Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.31 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31609391 | 0.74 | ALOX15 (0.43) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL28372316 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL28564397 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL5356727 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL2005730 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL9934488 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL2005732 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL16915952 | 0.70 | ALOX15 (0.40) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL4397520 | 0.70 | KDM4E (0.41) | ALOX15KDM4EALDH1A1HPGDGAA | |
| SCHEMBL28266639 | 0.70 | KDM4E (0.44) | ALOX15KDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11459310-B2 | LANCL ligands | LANDOS BIOPHARMA, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220127250-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2022087146-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-113748109-A | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127250-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | ALOX15 1739/4885KDM4E 3554/4885ALDH1A1 4156/4885 |
| US-11459310-B2 | LANCL ligands | LANCL2, LANCL1, ACSL1 | ALOX15 1177/4885KDM4E 3796/4885ALDH1A1 3541/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | ALOX15 283/4885KDM4E 855/4885ALDH1A1 1391/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | ALOX15 1739/4885KDM4E 3554/4885ALDH1A1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.